Oncolytics Biotech Shares Jump 9.8% on Heavy Trading
Oncolytics Biotech stock climbed 9.8% to $0.5382 in midday trading, with volume 134% above average. Analysts have a Moderate Buy consensus and $5.00 average target, while Weiss Ratings still rates it Sell. The company reported a quarterly loss of $0.08 per share, missing estimates by $0.03, and is developing pelareorep; institutions own 6.82%.
Oncolytics Biotech, a clinical-stage cancer immunotherapy developer, saw ONCY rise 9.8% in Wednesday midday trading. Shares reached $0.56 and last changed hands at $0.5382, up from a $0.49 close, as volume hit about 3.09 million versus a 1.32 million average.
The company’s lead candidate is pelareorep, an investigational reovirus-based formulation. Recent quarterly results showed a $0.08 per-share loss, $0.03 wider than expected. Its market value was $70.57 million, with a beta of 1.15 and institutional ownership of 6.82%.
The sharp move may draw retail traders and institutions to a thinly traded, clinical-stage biotech, raising volatility and risk. Patients hoping for new cancer immunotherapies could be affected if pelareorep advances or fails, though this price action alone does not change clinical prospects. Analysts’ split views and prior losses may shape investor confidence, while heavy volume could influence short-term liquidity and market perception.